Market News / Story
AbbVie (ABBV) Gets Two FDA Breakthrough Therapy Designations
·
AbbVie said the U.S. FDA granted two Breakthrough Therapy Designations for telisotuzumab adizutecan (Temab-A) in CRC and NSCLC. Material Details #DetailAI Analyst View1Two FDA Breakthrough Therapy tagsBTD can speed development and review, potentially pulling forward revenue timing if approvals follow.2Indications: CRC and NSCLCLarge oncology markets; success could be commercially significant.3Asset: Temab-A (telisotuzumab adizutecan)Adds another late-stage oncology…